Likewise, compared with chemotherapy, the CheckMate 026 study also showed no improvement in PFS or overall survival (OS) of patients with untreated stage IV or recurrent NSCLC and a PD-L1 expression level ≥5% who treated with nivolumab (mPFS 4.2 vs. 5.9 mons, p = 0.25; mOS 14.4 vs. 13.2 mons) (64). This evidence concerns the gene CD274 and non-small cell lung carcinoma.